N/A N=39 A Study to Evaluate Nicotine Uptake and Biomarkers in Adult Smokers Using mybluTM Electronic Cigarettes
Healthy Volunteers
Primary: Maximum Nicotine Concentration in Blood — 6.6; 7.9; 5.6; 6.0 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=200 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults
Dengue Fever
Primary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 — 557.4; 2047.4; 131.8; 119.6 titer
Phase 2 N=29 Enhancing Medication-based Analgesia in Humans
Pain · Cannabis · Opioid Use, Unspecified
Primary: Mean Change From Baseline in Seconds to Withdraw Hand From Cold Pressor Laboratory Pain Task — 25.4; 33.9; 31.7; 36.7 seconds — p=0.61
N/A N=11 Efficacy Study of the Music Glove Patients With Spinal Cord Injuries
Spinal Cord Injuries
Primary: Box and Blocks Test — 40.6; 40; 44.8; 39.0 blocks
N/A N=35 Toric Contact Lens Performance Study
Astigmatism
Primary: Near Visual LogMAR Acuity — -0.09; -0.02 LogMAR
Phase 3 N=331 Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Moderate to Severe Chronic Plaque-type Psoriasis
Primary: Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set) — 121; 92 Participants…
Phase 2 N=28 Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
Beta-thalassemia · Iron Overload
Primary: Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2* — 9.92; 11.73; 1.77; 11.93 milliseconds (msec)
Phase 2 N=474 A Study of Atezolizumab in Advanced Solid Tumors
Tumors
Primary: Non-progression Rate (NPR) at 18 Weeks — 26.8; 44.4; 29.6; 40.0 percentage of participants
N/A N=20 Serum Markers in Gluten Challenge
Celiac Disease
Primary: Crypt Depth to Villous Height Ratio — 2.05; 4.33; 1.19; 2.02 ratio — p=0.670
Phase 1 N=10 A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
Healthy
Primary: Percentage Reduction in Whole Brain Monoamine Oxidase (MAO)-B Availability Assessed by Positron Emission Tomography (PET) Imaging — 72.58; 2.43 Percent reduction
N/A N=983 An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
Colorectal Cancer
Primary: Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49 — 95.3 percentage of participants
Phase 1 N=21 A Study of TAS-205 for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Incidence of Adverse Events — 0; 3; 1; 1 participants
Phase 3 N=285 JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week…
N/A N=118 OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis
Joint Diseases · Rheumatoid Arthritis · Systemic Lupus Erythematosus
Primary: Daily Time in Moderate/Vigorous Physical Activity — 37.8; 31.6; 44.7; 31.6 Minutes
Phase 1 N=20 A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body
Renal Insufficiency · Healthy
Primary: Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24) — 3.97; 7.88…